Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL3 | P15374 | 4/20 | 0.53 |
| ▸ | UCHL1 | P09936 | 4/20 | 0.53 |
| ▸ | ALDH3A1 | P30838 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12856311 | 0.85 | ALDH1A1 (0.47) | ALDH3A1ALDH1A1ALDH2CA1CA2 | |
| SCHEMBL13627927 | 0.84 | ALDH3A1 (0.68) | UCHL3UCHL1ALDH3A1ALDH1A1ALDH2 | |
| SCHEMBL13627874 | 0.84 | ALDH3A1 (0.56) | UCHL3UCHL1ALDH3A1ALDH1A1ALDH2 | |
| SCHEMBL13627888 | 0.81 | APAF1 (0.60) | UCHL3UCHL1ALDH3A1ALDH1A1ALDH2 | |
| SCHEMBL13627933 | 0.81 | TP53 (0.53) | UCHL3UCHL1ALDH3A1ALDH1A1ALDH2 | |
| SCHEMBL13627932 | 0.81 | CA1 (0.59) | UCHL3UCHL1ALDH3A1ALDH1A1ALDH2 | |
| SCHEMBL13910749 | 0.80 | ALDH1A1 (0.58) | UCHL3UCHL1ALDH3A1ALDH1A1ALDH2 | |
| SCHEMBL13627928 | 0.80 | ALDH3A1 (0.51) | UCHL3UCHL1ALDH3A1ALDH1A1ALDH2 | |
| SCHEMBL13627931 | 0.80 | CA1 (0.56) | UCHL3UCHL1ALDH3A1ALDH1A1ALDH2 | |
| SCHEMBL13627934 | 0.79 | UCHL3 (0.50) | UCHL3UCHL1ALDH3A1ALDH1A1ALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612065-B2 | Inhibitors of c-JUN N-terminal kinases (JNK) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612065-B2 | Inhibitors of c-JUN N-terminal kinases (JNK) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | SALITURO FRANCESCO G | 2008-02-07 | — | — | US | disclosed |
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | SALITURO FRANCESCO G | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | MAP3K1, JUN, MAP3K7 | UCHL3 1695/4885UCHL1 1562/4885ALDH3A1 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.